Institute for International Research

Monday, April 14, 2008

B1: AM Symposium: The Fundamentals of Vaccine Formulation and Stability Testing

 CANCELLED- Unforseen Last-Minute Speaker Cancellation

Symposium Leader: Dr. Ian C. Boulton, Former Development Scientist, Formulation & Stability,

SANOFI-PASTEUR, President and Chief Scientific Officer, THE IMAGO GROUP

B2: PM Symposium: Uncover Innovative Vaccine Delivery Techniques and Their Impact on Formulation and Stability Studies

12:00 Symposium Registration Begins

1:00 Symposium Begins

2:30 30 Minute Networking & Refreshment Break

4:00 Symposium Concludes

Part I: Novel Adjuvants and Delivery Systems for Transdermal Immunization

Transdermal vaccine delivery (TVD) is a non-invasive, safe method of administering vaccines directly onto bare skin, offering a number of potential advantages over traditional needle-delivery. This technology is limited by the relative inefficiency of transport of large molecular weight vaccine antigens across intact skin. Recent evidence has shown that this barrier can be overcome by properly structured nanosized particles (nanocarriers). The specialized assembly of each type of nanocarrier gives each unique properties and different interactions within the lipid channels of the outermost level of the skin, the stratum corneum. TVD is also limited by the

availability of safe, effective adjuvants that can facilitate the immune response to vaccines delivered by this route. One class of ADP-ribosylating adjuvants has been shown to be safe and effective when administered transdermally and is capable of inducing both humoral and cellular immune responses to co-administered antigens.

• Identify strategies for transdermal vaccine delivery
• Explore the use of nanocarriers for transdermal vaccine delivery
• Describe safe, effective adjuvants that work both mucosally and transdermally

John D. Clements, PhD, Professor and Chair, Department of Microbiology and Immunology, Tulane University School of Medicine

Part II: Recent Advances In Nanotechnology For Mucosal Vaccine Delivery

Immunization via mucosal surfaces has great potential for the elimination of transmissible diseases, as this method can generate a protective immune response at the mucosal surface itself, which is the portal of entry for many pathogens. The present reality for vaccine delivery is different with most vaccines being administered parenterally using needles, which can mean that the potential of mucosal immunity is not realized. Can nanotechnology hold the key to enable us to alter the way vaccines are administered and harness mucosal immune responses in the generation of effective new vaccines? Nanotechnology has helped to facilitate enhanced stabilization of mucosal vaccines. Now indeed, developments in nanotechnology from both academic and industrial realms are helping to achieve the transformation to vaccine delivery through mucosal routes, with great possibilities for future vaccine design.

• Development of nanocarriers for mucosal targeting using surface engineering
• Utilization of co-delivery of vaccine and adjuvants using nanotechnology
• Design and development nanocarriers based on Vitamin E TPGS
• Composite inorganic and organic based nanocarriers for mucosal delivery of vaccines
• Enhancing stability by the utilization of nanotechnology
• Formulation development and design for pulmonary delivery of vaccines

Satyanaryana Somavarapu, PhD, Academic Fellow, The School of Pharmacy

University of London

Part III: Pros and Cons of Different Vaccine Delivery Systems

Open Session

For more information on speaking at this symposium, please contact Tricia Carle, TCarle@iirusa.com

Part IV: Hands On Q&A with Symposium Leaders